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Desmoids are locally aggressive proliferations of fibroblasts and
are classified as fibromatoses (Stout, 1951), a group including
Dupuytren’s contracture, plantar fibromatosis, Peyronie’s disease,
hypertrophic scars and low-grade fibrosarcomas. The incidence of
desmoids is only 2–4 per million per year (Reitamo et al, 1982),
but 2% of all desmoid tumours are associated with familial adeno-
matous polyposis (FAP) and the risk to an FAP patient is 1000
times that of the general population (Gurbuz et al, 1994).
Approximately 10% of FAP patients will develop a desmoid
(Church, 1994), 70% of which will be intra-abdominal (Gurbuz et
al, 1994) where they lead to major morbidity and mortality usually
as a result of small bowel obstruction and ischaemia, ureteric
obstruction or chronic sepsis.
The nature of desmoids remains controversial. Their locally
aggressive behaviour and potentially rapid progression (Church,
1995) suggests a neoplastic origin. Furthermore, intra-abdominal
desmoids removed surgically recur in as many as 88% of cases
(Lotfi et al, 1989) and there is evidence of response to
chemotherapy. On the other hand they never metastasize and there
is only one report of frankly malignant change in a desmoid (Soule
and Scanlon, 1962). In addition, almost 50% do not progress and
10% regress spontaneously (Church, 1995). Histologically they
resemble hypertrophic scars, consisting of mature fibroblasts
(Hunt et al, 1960) or myofibroblasts (Goellner and Soule, 1980)
with few mitoses and no atypia. Finally, they do not express telo-
merase (Scates et al, 1998) and these features are suggestive of a
non-neoplastic process.
There is specific evidence favouring a neoplastic origin for both
sporadic desmoids, which are associated with trisomies 8 (Dal Cin
et al, 1994) and 20 (Dal Cin et al, 1995) and FAP-associated
desmoids, where somatic mutations as well as the APC germline
mutation have been identified (Miyaki et al, 1993; Palmirotta et al,
1995). This is consistent with the two-hit loss of suppressor gene
hypothesis and is strong evidence that desmoids are indeed true
neoplasms.
The fundamental property of a neoplastic proliferation which
differentiates it from a reactive process is that it originates from a
single cell that acquires a selective growth advantage (Knudson,
1985). A neoplastic proliferation is therefore by definition mono-
clonal. At the late blastocyst stage of embryogenesis one or other
of the paternally or maternally-derived X-chromosomes is
randomly inactivated in each cell; that pattern is reproduced in
each daughter cell (Lyon, 1972) and is reliably transmitted during
malignant transformation (Wainscoat and Fey, 1990). Monoclonal
proliferations therefore display a non-random pattern of X-chro-
mosome inactivation, whereas polyclonal processes display a
random pattern of X-chromosome inactivation (Vogelstein et al,
1987). Initial techniques to assess clonality based on X-chromo-
some inactivation involved isoenzymes of glucose-6-phosphate
dehydrogenase (GAPDH) (Fialkow et al, 1967) but these were
inefficient and have now been replaced by a reliable polymerase
chain reaction (PCR)-based assay (Allen et al, 1992; Willman et
al, 1994).
Patterns of X-chromosome inactivation can be assessed at an 
X-linked locus if that locus can be identified separately on each 
X-chromosome and if it is possible to distinguish between the
active and inactivated X-chromosome. The human androgen
receptor gene (HUMARA) at Xcen-q13 fulfils these criteria. It
contains a polymorphic hypervariable short tandem repeat (STR)
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than 90% (Allen et al, 1992) as a result of the paternal and
maternal origins of each X-chromosome. Immediately upstream of
the CAG repeat there is a methylation-sensitive HpaII and HhaI
restriction enzyme site which is methylated in association with 
X-chromosome inactivation (Allen et al, 1992), preventing diges-
tion by either HpaII or HhaI. PCR amplification using oligo-
nucleotide primers directed towards HUMARA produces two
products, corresponding to one HUMARA sequence on each X-
chromosome. PCR carried out following HpaII/HhaI digestion
leads to two products if there is a random pattern of inactivation
but only one product if there is a non-random pattern (Figure 1).
By these means it is possible to distinguish between monoclonal
and polyclonal proliferations. The technique has been used to
demonstrate that sporadic desmoids are clonal in origin (Li et al,
1996; Alman et al, 1997; Lucas et al, 1997) but there are important
differences between sporadic and FAP-associated desmoids,
where there is a less obvious female preponderance (Gurbuz et al,
1994; Rodriguez-Bigas et al, 1994). In addition, sporadic
desmoids occur in intra-abdominal sites in less than 10% of cases
(Reitamo et al, 1986) and while most FAP-associated desmoids
follow trauma (Lotfi et al, 1989; Rodriguez-Bigas et al, 1994),
only about 30% of sporadic desmoids do so (Hayry et al, 1982).
Finally, these studies have used radiolabelled primers and phos-
phoimaging but the use of fluorescent-labelled primers and
commercial software analysis avoids radioactive materials and
enables more objective analysis (Delabesse et al, 1995). We used
this modification to examine patterns of X-chromosome inactiva-
tion at the HUMARA locus in FAP-associated desmoids.
MATERIALS AND METHODS
Tissues
Desmoid tumours and control blood samples were obtained from
female FAP patients undergoing surgery at St Mark’s Hospital.
Clinical data were obtained from the St Mark’s Polyposis Registry.
Colorectal cancer tissue samples were obtained as positive
controls. All tissue specimens were confirmed histologically.
DNA extraction and restriction enzyme digestion
DNA was obtained by proteinase K digestion, phenol–chloroform
extraction and ethanol precipitation. One microgram of each DNA
sample was incubated for 16 h at 37°C with 10 IU of restriction
enzyme (HhaI, Amersham Pharmacia, UK; HpaII, Promega,
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Figure 1: Schematic diagram of the HUMARA PCR-based assayUSA) in a final volume of 20 ml according to the manufacturers’
recommendations. In each case a control sample was incubated in
a similar volume without restriction enzyme.
PCR amplification
A 20 ml PCR was carried out using 1 ml of each incubated DNA
sample in 12.9 ml water, 2 ml of 2.5 mM fluorescent-labelled
oligonucleotide HUMARA primers (5¢-HEX-GCTGTGAAG-
GTTGCTGTTCCTCAT-3¢ and 5¢-TCCAGAATCTGTTCCA-
GAGCGTGC-3¢), 1.6 ml dNTPs, 0.4 ml 7-deaza-2¢-deoxy GTP
(Boehringher Mannheim), 2 ml reaction buffer (500 mM; potas-
sium chloride (KCl); 100 mM Tris–HCl, pH 9; 1% Triton® ´ 100;
25 mM magnesium chloride (MgCl2), and 0.1 ml Taq DNA poly-
merase. The primers were provided by Imperial Cancer Research
Fund’s laboratories. Initial denaturation was carried out in a
preheated thermal cycler at 95°C for 5 min, followed by 35 cycles
of 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. Final exten-
sion continued for a further 5 min. Combination with loading
buffer and gel electrophoresis through 2% agarose confirmed PCR
products and following migration using a 10% denaturing poly-
acrylamide gel on an automatic Applied Biosystems ABI 377
sequence analyser, fluorescent peaks were identified using the
Genescan IITM software. All assays were repeated in triplicate.
Interpretation
Superimposing GenescanTM peaks for individual samples before
and following restriction enzyme digestion gave an immediate
impression of clonality (Figure 2) but an inactivation or clonality
ratio (CR) was calculated for each according to a previously
described technique (Willman et al, 1994). In this way the amplifi-
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Figure 3: Standard curve of clonality ratio (CR) v. percentage clonal cells
for control samplescation ratio (AR) for a sample is PHMW/PLMW where PHMW is the
PCR product of the high molecular weight product and PLMW is the
PCR product of the low molecular weight product. PHMW/PLMW is
calculated as [Astut(HMW) + Aprim(HMW)]/[Astut(LMW) + Aprim(LMW)] where
Aprim is the area (or height) of the primary peak and Astut is the area
(or height) of the highest molecular weight stutter peak on the
GenescanTM image of that sample. The CR is ARundig/ARdig where
ARundig is the amplification ratio of undigested tumour DNA and
ARdig is the amplification ratio of digested tumour DNA. If the CR
is greater than 1 the reciprocal figure is used. The CR provides an
objective assessment of the degree to which the lower or higher
molecular weight PCR product is absent following restriction
enzyme digestion and therefore the degree to which the sample is
clonal. Clonality ratios between 1 and 0 are obtained where one
indicates a polyclonal origin and zero indicates a monoclonal
origin for the sample. To allow for unequal lyonization (Fey et al,
1992), the CR is divided by the CR calculated in a similar fashion
for the corresponding blood control (El Kassar et al, 1998). A
final, corrected CR ≤ 0.5 has been considered indicative of a clonal
composition (Li et al, 1996). To improve objectivity, we calculated
CRs for samples of proportionally mixed colorectal cancer DNA
(considered to be 100% clonal) and blood lymphocyte DNA
(considered to be 0% clonal). It was then possible to construct a
standard curve of CR against percentage clonal cells (Figure 3) such
that the proportion of clonal cells in each desmoid sample could be
deduced from the curve when the CR was known for that sample.
RESULTS (table 1)
Sixteen intra-abdominal and nine abdominal wall samples of
histologically confirmed desmoid tissue were available from 11
female FAP patients. Control blood samples were available for
seven of the patients, whose ages ranged from 16 to 45 years
(median 28 years). Two patients had been treated with non-
steroidal anti-inflammatory medication and two with toremifene,
an anti-oestrogen. One had been treated with chemotherapy 3
years earlier but none had received radiotherapy. The HUMARA
sequence was informative in 12 intra-abdominal and nine abdom-
inal wall samples from nine of the 11 patients. All control blood
samples were informative, although two related to non-informa-
tive desmoid samples. Informative results were achieved more
frequently with HhaI than HpaII, but in those samples which were
informative with both enzymes, very similar CRs were obtained
with each. Multiple samples from individual patients produced
similar results apart from samples 8, 9 and 17 (Table 1), which
yielded unusually high CRs compared to other samples from the
same patient. Clonality ratios calculated from peak areas or peak
heights yielded almost identical results. As expected, all primary
peaks observed were multiples of 3 base pairs apart due to the tri-
nucleotide repeat within HUMARA (Figure 2). Samples from six
patients were found to have a final CR ≤ 0.5 and those from a
further three had a CR > 0.5. The corresponding percentage of
clonal cells calculated from standard curves ranged from 0% to
75% (median 66%) for all patients or 65% to 75% (median 71%)
for those with a CR ≤ 0.5. Clonality ratios for the control blood
samples are shown in Table 1. The mean figure of 0.76 was used to
correct for unequal lyonization in patients for whom a control
sample was unavailable. There was no obvious relationship
between clonality and either germline mutation, somatic mutation
or previous treatment, although it is of interest to note that patient
7 had received chemotherapy and her desmoid samples had a low
proportion of clonal cells.
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Table 1 Clonality ratios and clonal cell proportions
Patient Age Sample Site Germline Somatic CR Control CR Controlled CR Final CR % clonal
mutationa mutationa cells
1 42 1 Intra-abdominal 1392 ND NI 0.74 NI NI NI
2 Intra-abdominal NI 0.74 NI NI NI
2 25 3 Intra-abdominal 1084 1542 0.37 0.85 0.44 0.44 73
3 24 4 Intra-abdominal ND ND 0.50 0.76 0.66 0.66 42
4 40 5 Abdominal wall ND 1433 0.32 0.73 0.44 0.50b 65
6 Abdominal wall 0.40 0.73 0.55
7 Abdominal wall 0.36 0.73 0.49
8 Abdominal wall 0.52 0.73 0.71
9 Abdominal wall 0.61 0.73 0.84
10 Abdominal wall 0.20 0.73 0.27
11 Abdominal wall 0.18 0.73 0.25
12 Abdominal wall 0.35 0.73 0.48
5 45 13 Intra-abdominal ND ND NI 0.78 NI NI NI
14 Intra-abdominal NI 0.78 NI NI NI
6 31 15 Intra-abdominal 1461 1483 0.33 0.67 0.49 0.49 66
7 28 16 Intra-abdominal 1450 ND 0.63 0.84 0.75 0.72b 32
17 Intra-abdominal 0.75 0.84 0.89
18 Intra-abdominal 0.57 0.84 0.68
19 Intra-abdominal 0.50 0.84 0.60
20 Intra-abdominal 0.60 0.84 0.71
21 Intra-abdominal 0.60 0.84 0.71
8 20 22 Intra-abdominal 1397 1543 0.36 0.76 0.47 0.47 69
9 45 23 Intra-abdominal ND ND 0.32 0.76 0.42 0.42 75
10 16 24 Abdominal wall ND 1462 0.71 0.76 0.93 0.93 0
11 22 25 Intra-abdominal 233 ND 0.30 0.71 0.42 0.42 75
CR = clonality ratio; control CR = control not available (Mean of available control CRs used); NI = non-informative; ND = not detected. aAPC mutation detected
in previous work; bMean CR for multiple samples.DISCUSSION
As screening for FAP becomes more efficient and surgery more
sophisticated, the relative importance of extracolonic manifesta-
tions of FAP is increasing (Belchetz et al, 1996). In addition, the
combination of the location and unpredictable nature of FAP-asso-
ciated desmoids means that they are one of the two leading causes
of death in FAP patients who have undergone prophylactic colec-
tomy (Nugent et al, 1993). Desmoids, however, remain poorly
understood and as a result treatment is poor and mortality high
(Rodriguez-Bigas et al, 1994). Currently the commonest forms of
treatment for desmoids are sulindac, tamoxifen or toremifene
(Brooks et al, 1992; Tsukada et al, 1992), radiotherapy (Kiel and
Suit, 1984), cytotoxic chemotherapy (Lynch et al, 1994; Hamilton
et al, 1996) or excisional surgery. All of these modalities have
limited efficacy and potential problems. An understanding of the
nature of desmoids will encourage the development of more
appropriate tailored treatment protocols.
Assessment of clonality by the examination of patterns of X-
chromosome inactivation has proved to be a reliable technique and
has demonstrated that FAP-associated desmoid in our series are
true neoplasms. Although the number of patients involved was
small, most other authors using a similar technique have used even
fewer. This can be explained by the low incidence of desmoids and
an increasing tendency to avoid surgery for FAP-related desmoid
disease. The only limitations of the HUMARA PCR-based assay
are a requirement for female tissue samples and heterozygous
HUMARA sequences. As reported by others (Li et al, 1996) we
found the addition of 7-deaza-2¢-deoxy GTP to the dNTP mixture
improved the PCR process significantly. This manoeuvre is said to
reduce the formation of DNA secondary structures when carrying
out PCR assays whose products contain CpG-rich regions (Mutter
and Boynton, 1995).
The technique enables samples to be easily and rapidly recog-
nized as informative or non-informative and an idea of the result
may be obtained by simple observation of the Genescan™ images.
Other authors using radiolabelled primers and phosphoimaging
have relied on visual assessment alone to designate clonality
(Alman et al, 1997). The use of fluorescent-labelled primers not
only avoids the safety and environmental issues of radioactive
material but allows a quantitative analysis of clonality through the
calculation of a CR. The only disadvantage is the difficulty in
relating the CR to the true clonality of a sample. Clonality ratios of
1 do not occur as there is frequently unequal lyonization of normal
tissues. Clonality ratios of 0 do not occur as there is contamination
of tumour specimens with other non-clonal cells such as lympho-
cytes, peritoneal cells and vascular elements. Microdissection
techniques have enabled lower CRs to be obtained with other
tumour specimens, including sporadic desmoids (Lucas et al,
1997), but we have found the technique to be difficult and
unhelpful with FAP-associated desmoids due to their often sparse
cellularity.
A positive clonality result is indicated by a significant mono-
clonal contamination of a polyclonal background and it has been
shown that the percentage of clonal cells can be estimated with an
error of ± 10% and that a clonal population of cells can be detected
if they represent greater than 10–15% of cells in a polyclonal back-
ground (Delabesse et al, 1997). All of our samples comprised a
greater proportion of clonal cells than this minimum. The use of
blood lymphocytes as control tissue for distinguishing between
skewed inactivation and clonal proliferation has been shown to be
reliable in young females (Tonon et al, 1998); the median age in
our series was 28 years.
The confirmation that FAP-associated desmoids are neoplastic
improves understanding of their development. Fibroblasts in
patients with FAP are known to be abnormal (Pfeffer et al, 1976).
White plaques or strands known as desmoid precursor lesions
(DPLs) develop from fibroblasts in the mesentery of a third of
post-operative patients with FAP and mesenteric fibromatosis
(tethering or puckering of the mesentery not amounting to a mass
but detectable on computerized tomography scanning) occurs in
20–25% of cases (Clark et al, 1998). Finally around 10% develop
a desmoid. Our results indicate that FAP-associated desmoids are
true neoplasms which may fit into a cascade analogous to the
multi-step process in cancer development where separate clonal
expansions follow individual mutations (Vogelstein and Kinzler,
1993). It may be that fibroblasts in FAP containing an APC
germline mutation are at risk of forming a DPL, although this
mechanism is unclear and it has been shown that transient trans-
fection of wild-type APC into desmoid cell cultures actually
decreases proliferation (Li et al, 1998). During the peri- or post-
operative period, a fibroblast within the DPL may acquire a
somatic mutation and develop a selective growth advantage,
enabling clonal expansion to form a true desmoid.
This study has addressed the question of the nature of FAP-asso-
ciated desmoids. Whether it will allow rationalization of treatment
protocols for these locally aggressive tumours which have high
mortality in a young population, remains to be seen. It suggests the
need for further investigation into the role of antisarcoma
chemotherapy, a potentially lengthy and toxic regime whose effi-
cacy is as yet unclear. Of interest, desmoid samples from the one
patient in this study who had previously received chemotherapy
had a low clonality ratio, but our (unpublished) experience of
chemotherapy is disappointing and we are not yet convinced of its
role in the treatment of desmoids. Finally, further work is required
to ascertain the nature of the somatic mutation occurring in the
perioperative period which precipitates clonal expansion to form
an FAP-associated desmoid.
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